近期，公司已将上述现金管理产品赎回，收回本金7,000万元，取得实际收益47.44万元， 与预期收益不存在重大差异。 二、关联关系说明 证券代码：300463 证券简称：迈克生物 公告编号：2024-045 迈克生物股份有限公司 关于使用部分闲置募集资金进行现金管理 到期赎回的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司第五届董事会第十三次会议、第五届监事会第十二次会议审议通过 了《关于继续使用部分闲置募集资金进行现金管理的议案》，为提高暂时闲置募集资金的使用 效率，增加资金收益，在保证募集资金投资项目建设和募集资金正常使用的情况下，同意使用 不超过人民币15,000万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、 满足保本要求的理财产品，自公司第五届董事会第十三次会议审议通过之日起十二个月内有效， 在上述使用期限及额度内，资金可以循环滚动使用。闲置募集资金现金管理到期后将及时归还 至募集资金专户，同时授权公司董事长行使相关投资决策权，财务负责人办理具体相关事宜。 公司已于2024年3月11日在巨潮资讯网刊登了《 ...

迈克生物股份有限公司 2023 年度内部控制自我评价报告 迈克生物股份有限公司 2023 年度内部控制自我评价报告 迈克生物股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以 下简称企业内部控制规范体系），结合迈克生物股份有限公司（以下简称"公司"）内 部控制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司截 至 2023 年 12 月 31 日的内部控制有效性进行了评价。 一、 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内 部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监 事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈 述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信 息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有 局限性，故仅能为实现上述目标提供合理保证。此外 ...

迈克生物股份有限公司 募集资金存放与使用情况专项报告 二〇二三年度 关于迈克生物股份有限公司2023年度募集资金存放与使用 情况专项报告的鉴证报告 信会师报字[2024]第ZD10092号 迈克生物股份有限公司全体股东： 我们接受委托，对后附的迈克生物股份有限公司（以下简称"迈 克生物"）2023年度募集资金存放与使用情况专项报告（以下简称"募 集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 迈克生物董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《深 圳证券交易所创业板上市公司自律监管指南第2号——公告格式 （2023年修订）》的相关规定编制募集资金专项报告。这种责任包括 设计、执行和维护与募集资金专项报告编制相关的内部控制，确保募 集资金专项报告真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 三、工作 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-042 迈克生物股份有限公司 关于继续购买董监高责任险的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"迈克生物"或"公司"）于2024年4月24日分别召开第五 届董事会第十四次会议及第五届监事会第十三次会议，审议了《关于继续购买董监高责任险的 议案》。为完善风险控制体系，保障公司董事、监事及高级管理人员的权益，促进相关责任人 员充分行使权力、履行职责，促进公司健康发展，根据《上市公司治理准则》的相关规定，公 司拟为公司及全体董事、监事、高级管理人员以及其他相关责任人员投保责任险。因该事项与 全体董事、监事、高级管理人员存在利害关系，因此全体董事、监事在审议本事项时均回避表 决，该事项将直接提交公司股东大会审议。现将有关事项公告如下： 一、董监高责任险方案 1、投保人：迈克生物股份有限公司 2、被保险人：公司及全体董事、监事、高级管理人员以及其他相关责任人员 3、每次及累计赔偿限额：不超过人民币4000万元/年（具体以保险公司最终报价审批数据 为准）； 4、保费 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-043 迈克生物股份有限公司 关于部分募投项目子项目变更及金额调整 并进行部分募投项目延期的公告 证券代码:300463 证券简称:迈克生物 公告编号:2024-043 一、募集资金基本情况 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发行股票注册 的批复》（证监许可〔2021〕412 号）的核准，迈克生物股份有限公司本次向特定对象发行 人民币普通股（A 股）56,000,000 股，每股面值 1 元，发行价格为 28.11 元/股，募集资金总 额为人民币 1,574,160,000.00 元，扣除发行费用人民币（不含增值税）16,703,564.36 元，实际 募集资金净额为人民币 1,557,456,435.64 元。2022 年 1 月 25 日，招商证券股份有限公司将扣 除保荐机构（联席主承销）保荐承销费 15,741,600.00 元（含增值税）后的上述认购资金的剩 余款项人民币 1,558,418,400.00 元划转至公司本次向特定对象发行开立的募集资金专项存储账 户中。立信会计师事务所（特殊普通合伙）已对募集资 ...

一、公司内部控制评价工作情况 招商证券股份有限公司 关于迈克生物股份有限公司 2023 年度内部控制自我评价报告的核查意见 招商证券股份有限公司（以下简称"招商证券"）作为迈克生物股份有限公司 （以下简称"迈克生物"、"公司"）向特定对象发行股票的保荐机构，根据《证券 发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券 交易所上市公司自律监管指引第 13 号—保荐业务》等有关规定，对迈克生物 2022 年度内部控制自我评价报告进行了审慎核查，核查情况如下： 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。 纳入评价范围的主要单位包括：母公司及下属控股子公司。纳入评价范围单 位资产合计占公司合并财务报表资产总额的 100%，营业收入合计占公司合并财务 报表营业收入总额的 100%。 纳入评价范围的主要业务和事项包括：内部环境、风险评估、组织架构、人 力资源、资金管理、资产管理、销售业务、采购业务、工程项目、研究与开发、担 保业务、财务报告、内部信息传递及对控股子公司的管理控制等方面。 上 ...

招商证券股份有限公司 关于迈克生物股份有限公司 部分募投项目子项目变更及金额调整 并进行部分募投项目延期的核查意见 招商证券股份有限公司（以下简称"招商证券"）作为迈克生物股份有限公司 （以下简称"迈克生物"、"公司"）向特定对象发行股票的保荐机构，根据《证券 发行上市保荐业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金管 理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交易所 上市公司自律监管指引第 13 号—保荐业务》等有关规定，对公司部分募投项目 子项目变更及金额调整并进行部分募投项目延期情况进行了核查，具体情况如下： 一、 变更募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发 行股票注册的批复》（证监许可〔2021〕412 号）的核准，公司本次向特定对象发 行人民币普通股（A 股）56,000,000 股，每股发行价格为 28.11 元/股，募集资金 总额为人民币 1,574,160,000.00 元，扣除发行费用人民币（不含增值税 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-027 迈克生物股份有限公司 迈克生物股份有限公司（以下简称"迈克生物"或"公司"）《2023年年度报告》及其摘要将于 2024年4月25日在巨潮资讯网（http://www.cninfo.com.cn）披露。 为了让广大投资者进一步了解公司2023年年度经营业绩、发展战略情况，公司拟定于2024 年4月30日（星期二）15:00-17:00在价值在线举办2023年度业绩说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登陆价值在线（https://eseb.cn/1dVJpPy4cms）参与本次 年度业绩说明会。 出席本次说明会的人员有：公司总经理吴明建、财务总监尹珊、董事会秘书史炜、独立董 事傅代国、保荐代表人鄢坚。 为充分尊重投资者、提升交流的针对性，现就公司2023年度业绩说明会提前向投资者公开 征集问题，广泛听取投资者的意见和建议。投资者可于2024年4月30日（星期二）前访问 https://eseb.cn/1dVJpPy4cms或使用微信扫描下方小程序码，进入问题征集专题页面。公司将在 2023年度业绩说明会上，对投资者 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-036 迈克生物股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集资金管理和使 用的监管要求》（证监会公告〔2022〕15号）《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司自律监管指南第2号—— 公告格式》《深圳证券交易所创业板上市公司业务办理指南第6号——信息披露公告格式》的相 关规定，将迈克生物股份有限公司（以下简称"公司"）2023年度募集资金存放与实际使用情 况报告如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发行股票注册 的批复》（证监许可〔2021〕412 号）的核准，迈克生物股份有限公司（以下简称"公司"）本次 向特定对象发行人民币普通股（A 股）56,000,000 股，每股发行价格为 28.11 元/股，募集资 ...

Regional Revenue Breakdown - Northeast region revenue: 225,520,785.38 RMB, accounting for 7.79% of total revenue[1] - North China region revenue: 331,306,222.13 RMB, accounting for 11.44% of total revenue[1] - East China region revenue: 517,166,191.62 RMB, accounting for 17.86% of total revenue[1] - Central China region revenue: 226,862,637.73 RMB, accounting for 7.83% of total revenue[1] - South China region revenue: 182,913,613.90 RMB, accounting for 6.32% of total revenue[1] - Northwest region revenue: 219,220,451.56 RMB, accounting for 7.57% of total revenue[1] - Southwest region revenue: 1,090,898,703.75 RMB, accounting for 37.67% of total revenue[1] - Overseas region revenue: 101,880,905.95 RMB, accounting for 3.52% of total revenue[1] Sales Channels - Direct sales revenue: 1,056,481,998.80 RMB, accounting for 36.48% of total revenue[1] - Distribution sales revenue: 1,839,287,513.22 RMB, accounting for 63.52% of total revenue[1] Product Development and R&D - The company has established a "8+1" product technology platform, including biochemistry, immunity, blood cells, coagulation, urine, molecular, blood type, pathology, and rapid testing, with 512 registered certificates for self-developed in vitro diagnostic products[22] - In 2023, the company completed the development of 30 raw materials, including 19 antibodies, 6 antigens, and 5 chemical raw materials, with a self-sufficiency rate of core raw materials exceeding 50%[22] - The company added 64 new products during the reporting period, bringing the total number of registered products to 512[28] - The company completed 71 R&D projects in 2023, with 572 projects still in progress, and invested a total of 414.02 million yuan in R&D[40] - The company's R&D team consists of 1,172 personnel, with 577 focused on clinical testing and 595 on other diagnostic areas[40] - The company's R&D investment increased by 22.34% to 414 million yuan, with R&D personnel growing by 149 to 1,172, accounting for 34.86% of total employees[88] - The company obtained 64 new domestic product registrations in 2023, bringing the total to 512, including 485 reagents and 27 instruments[119] - The company launched the LABAS MIX fully automated laboratory intelligent assembly line, integrating ten functions such as automatic quality control detection and multi-mode sample input[119] - The company added 19 new reagent product registrations for its acridinium ester direct chemiluminescence technology platform, bringing the total to 102[119] Financial Performance - The company's revenue for the four quarters of 2023 were 676.4 million, 704.3 million, 734.4 million, and 780.7 million respectively[29] - The net profit attributable to shareholders for the four quarters of 2023 were 116.9 million, 58.0 million, 93.8 million, and 43.9 million respectively[29] - The net cash flow from operating activities for the four quarters of 2023 were 167.0 million, 242.7 million, 207.4 million, and 284.4 million respectively[29] - The company's revenue for the reporting period was 2.896 billion yuan, a year-on-year decrease of 19.75%, with net profit attributable to shareholders of 313 million yuan, a year-on-year decrease of 55.86%[61] - Total operating revenue for 2023 was RMB 2,895,769,512.02, a decrease of 19.75% compared to 2022[62] - Revenue from self-developed products accounted for 64.94% of total revenue, amounting to RMB 1,880,368,645.95, a decrease of 18.67% year-over-year[62] - Revenue from agent products was RMB 981,448,342.17, accounting for 33.89% of total revenue, a decrease of 21.87% compared to 2022[62] - The company's net profit was 212,756,122.56, compared to 368,913,140.91 in the previous period[108] - The company's total comprehensive income was 199,197,097.20, compared to 384,841,761.44 in the previous period[108] - Revenue for 2023 was 2,895.77 million yuan, a decrease of 19.75% compared to the previous year[144] Market Expansion and Distribution - The company's self-developed products cover over 8,000 medical institutions nationwide, with coverage rates of 24% in secondary hospitals and 50% in tertiary hospitals[35] - The company has established partnerships with 566 distributors, and its products are available in 118 countries and regions, with overseas markets becoming a key focus for expansion[35] - The company has invested in overseas market expansion, setting up 2 overseas platform companies, 1 overseas office, and 1 overseas transit warehouse, with products covering 118 countries and regions[50] - The company has a wide marketing service network, with 12 channel subsidiaries, 17 offices, and 622 sales personnel in the domestic market, serving over 8,000 terminal customers[59] Product Sales and Inventory - The company's autonomous products achieved sales revenue of 1.714 billion yuan, a year-on-year increase of 4.92%, with 4,016 large instruments and production lines shipped to the terminal market[58] - Sales of immunodiagnostic reagents reached RMB 952 million, an increase of 18.68% year-over-year[70] - Sales of biochemical reagents were RMB 577 million, an increase of 2.54% year-over-year[70] - Sales of molecular diagnostic reagents dropped significantly to RMB 7.0451 million, a decrease of 98.79% year-over-year[70] - Inventory balance decreased by 12.7% at the end of 2023 compared to the previous year[71] - Accounts receivable balance decreased by 14.48% at the end of 2023 compared to the previous year[71] - Revenue from in vitro diagnostic products decreased by 19.75% to 2,895,769,512.02 yuan, with a gross margin of 55.27%[73] - Sales volume of diagnostic reagents dropped by 44.47% to 3.3274 million boxes, while production volume decreased by 44.57% to 3.1403 million boxes[73] - Sales volume of diagnostic instruments (large type) increased by 4.43% to 3,462 units, with production volume rising by 18.82% to 3,555 units[73] - Sales volume of diagnostic assembly lines surged by 122.15% to 351 units, with production volume increasing by 107.03% to 383 units[73] - The company achieved a total of 4,016 units (lines) of large instruments and assembly lines delivered to the market, including 189 biochemical and immune assembly lines and 162 blood assembly lines[74] - The company's diagnostic assembly line inventory increased by 77.5% to 71 units, driven by the promotion of full laboratory automation assembly lines[89] Financial Position and Assets - The company's debt-to-asset ratio decreased to 18.57% by the end of the reporting period, a reduction of 1.49 percentage points compared to the previous year[42] - The company's financing costs decreased by 7% year-on-year, with short-term and long-term loan ratios adjusted to 29%[42] - Cash and cash equivalents at the end of the period increased to 811,362,294.43 yuan, up from 564,293,033.08 yuan at the beginning of the period[110] - Net cash flow from financing activities was -152,750,581.74 yuan, compared to 930,049,187.87 yuan in the previous period[110] - Total assets at the end of the period were 8,119,249,307.93 yuan, slightly down from 8,168,350,292.26 yuan at the beginning of the period[126] - Fixed assets increased to 2,186,644,511.57 yuan from 1,979,045,213.17 yuan[126] - Short-term borrowings decreased to 144,647,498.10 yuan from 248,075,777.91 yuan[126] - The company's total equity at the end of the period was 6,611.462 million yuan[137] - The company allocated 28 million yuan for surplus reserves[135] - The company distributed 286.635 million yuan to shareholders[135] - The company's capital reserve increased by 973,812.19 yuan[135] - The company's total assets at the end of the period were 6,384.825 million yuan[137] - Inventory increased to 531,716,615.34 from 511,178,091.88, reflecting a growth of 4.02%[151] - Total current assets decreased to 4,612,719,595.24 from 4,750,174,683.29, a decline of 2.89%[151] - Long-term equity investments decreased to 1,011,979,841.96 from 1,030,817,115.07, a reduction of 1.83%[151] - Fixed assets increased significantly to 1,090,901,724.56 from 643,509,759.96, a growth of 69.53%[151] - Development expenditure rose to 35,090,057.08 from 26,227,525.22, an increase of 33.79%[151] - Cash received from sales of goods and services increased to 1,750,685,765.23 from 1,577,681,416.05, a growth of 10.97%[156] - Net cash flow from operating activities surged to 852,137,792.51 from 479,718,443.09, an increase of 77.63%[156] - Cash outflow for investments decreased to 2,608,658,144.10 from 3,305,095,470.26, a reduction of 21.07%[156] - Cash received from tax refunds increased significantly to 67,558,608.47 from 3,573,372.16, a growth of 1790.47%[156] - Total assets increased to 7,106,384,593.18 from 6,809,623,435.59, a growth of 4.36%[151] Corporate Governance and Shareholders - The company has 20 wholly-owned or controlled subsidiaries, including 12 domestic trading companies and 2 overseas trading companies, with R&D functions distributed across Chengdu, Hangzhou, Beijing, and the US[35] - The company released 80 temporary announcements and completed 59 investor research sessions in 2023[100] - The company's board consists of 9 members, including 3 independent directors[103] - The total restricted shares at the end of the reporting period were 117,119,807[104] - The number of ordinary shareholders at the end of the reporting period was 39,869, up from 38,606 at the end of the previous month[115] - The China Construction Bank-Huabao CSI Medical ETF exited the top ten shareholders, while the China Construction Bank-GF Healthcare Equity Fund was newly added[131] Quality Management and Traceability - The company has established a comprehensive quality management system, including 100,000-level clean rooms for microbial testing and barcode management for full traceability of product quality[49] - The company has established a leading metrological traceability system in the industry, being the first Chinese enterprise representative in the JCTLM international metrological traceability system[54] Product Line and Strategy - The company's products include a wide range of diagnostic platforms, such as biochemistry, immunology, hematology, and molecular diagnostics, with integrated automation solutions[34] - The company has a complete product line strategy, covering biochemical, immunological, hematological, molecular diagnostics, POCT, pathology, and raw materials, making it one of the most comprehensive IVD companies in China[54] Cost Management and Supply Chain - The company focuses on cost management, optimizing supply chain procurement and increasing the self-production rate of raw materials to reduce production costs[46] Guarantees and Subsidiaries - The total approved guarantee amount for subsidiaries during the reporting period was 143,000[95] - The actual guarantee amount issued during the reporting period was 45,022.77[95] - The total approved guarantee amount for subsidiaries at the end of the reporting period was 93,000[98] - The actual guarantee balance for subsidiaries at the end of the reporting period was 6,522.77[98] Financial Assets and Liabilities - The company's financial liabilities are initially classified as either financial liabilities measured at fair value through profit or loss or financial liabilities measured at amortized cost[181] - Financial assets measured at amortized cost include interest calculated using the effective interest method during the holding period, which is recognized in current profit or loss[183] - Financial assets measured at fair value through other comprehensive income (equity instruments) are initially measured at fair value, with related transaction costs recognized in current profit or loss[184] - Financial liabilities measured at fair value through profit or loss are initially measured at fair value, with related transaction costs recognized in current profit or loss[184] - The company terminates recognition of existing financial liabilities when substantial modifications are made to the contract terms, and the modified financial liability is recognized as a new financial liability[186] - The company measures the loss allowance for receivables at an amount equal to the lifetime expected credit losses, regardless of whether they contain a significant financing component[187] - The company's financial assets are initially classified as financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income (debt instruments), or financial assets measured at fair value through profit or loss[193] - Financial assets measured at fair value through other comprehensive income (debt instruments) are initially measured at fair value, with related transaction costs included in the initial recognition amount[196] - Upon derecognition, the cumulative gain or loss previously recognized in other comprehensive income is reclassified from other comprehensive income to retained earnings[197] - The difference between the consideration paid and the carrying amount of the financial liability is recognized in current profit or loss upon derecognition[198] Acquisitions and Equity Transfers - The company transferred 100% equity of Xinjiang Mike for 10.3852 million yuan on August 8, 2023[146] - The company acquired 100% equity of Beijing Dawei Microorganism Technology Co., Ltd. in November 2020 and March 2022[146] - As of September 30, 2023, Dawei Microorganism had no operational business and was planned for deregistration[146]